trial

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

NCTId NCT02332798
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 39 (actual)
Sponsored by Biogen
Primary completion 2015-04-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-01-06
Primary completion
2015-04-15
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-04958242

Sponsors

BiogenLead Sponsor

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE1
Primary Completion Date
2015-04-15
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242
drug
lead_sponsor
Biogen
company
indication
Schizophrenia
indication
Schizophrenia
indication